menu
    • menu

    Company profile for NRG Therapeutics

    NEW Drugs in Dev: 1
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    NRG Therapeutics is a drug discovery company focussed on therapeutic approaches that will restore mitochondrial function and slow or halt the progression of neurodegenerative diseases such as Parkinson’s disease, Alzheimer’s disease and motor neurone disease. Founded in 2018 by a team of experienced biotech and pharmaceutical industry professionals, with a background in neuroscience drug discovery, NRG Therapeutics will in...
    NRG Therapeutics is a drug discovery company focussed on therapeutic approaches that will restore mitochondrial function and slow or halt the progression of neurodegenerative diseases such as Parkinson’s disease, Alzheimer’s disease and motor neurone disease. Founded in 2018 by a team of experienced biotech and pharmaceutical industry professionals, with a background in neuroscience drug discovery, NRG Therapeutics will initially focus on the discovery and development of brain penetrant mitochondrial permeability transition pore inhibitors for the treatment of Parkinson’s disease.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    NRG Therapeuticsunitedkingdom_new Flag
    Country
    Country
    United Kingdom
    Address
    Address
    Cambridge, Cambridgeshire GB
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    http://www.nrgtherapeutics.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/nrgtherapeutics/about/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Clinical Outsourcing

    Clinical Outsourcing

    Not Confirmed

    envelop Contact Supplier

    Clinical Outsourcing

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    NRG Therapeutics Initiates Phase 1 Trial For NRG5051 In ALS/MND
    NRG Therapeutics Initiates Phase 1 Trial For NRG5051 In ALS/MND

    08 Jan 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-01-08/nrg-therapeutics-announces-first-participants-dosed-in-its-first-in-human-phase-1-clinical-trial-of-nrg5051-which-is-being-developed-as-a-disease-modi

    PHARMIWEB
    08 Jan 2026
    Share Share
    NRG Therapeutics Appoints Paul Thompson Chief Development Officer
    NRG Therapeutics Appoints Paul Thompson Chief Development Officer

    01 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/01/3196724/0/en/NRG-Therapeutics-Announces-Further-Expansion-with-the-Appointment-of-Paul-Thompson-as-Chief-Development-Officer.html

    GLOBENEWSWIRE
    01 Dec 2025
    Share Share
    NRG Therapeutics Announces Senior Appoints as it Advances NRG5051
    NRG Therapeutics Announces Senior Appoints as it Advances NRG5051

    23 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/23/3171716/0/en/NRG-Therapeutics-Announces-Senior-Appointments-as-it-Advances-NRG5051-Towards-First-in-Human-Clinical-Studies.html

    GLOBENEWSWIRE
    23 Oct 2025
    Share Share
    NRG Secures £50M Series B Funding for Parkinson's Research
    NRG Secures £50M Series B Funding for Parkinson's Research

    08 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/08/3145831/0/en/NRG-Therapeutics-Announces-Oversubscribed-50m-67m-Series-B-Financing-to-Deliver-Clinical-Data-in-Parkinson-s-and-Proof-of-Concept-in-ALS-MND.html

    GLOBENEWSWIRE
    08 Sep 2025
    Share Share
    NRG Therapeutics Selects NRG5051, Receives Michael Foundation Grant
    NRG Therapeutics Selects NRG5051, Receives Michael Foundation Grant

    31 Oct 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/10/31/2972343/0/en/NRG-Therapeutics-Selects-First-Development-Candidate-NRG5051-and-Secures-Grant-from-The-Michael-J-Fox-Foundation-for-Development-of-mPTP-Inhibitors-to-Treat-Neurodegenerative-Disea.html

    GLOBENEWSWIRE
    31 Oct 2024
    Share Share
    NRG Therapeutics Awarded Grant From Target ALS
    NRG Therapeutics Awarded Grant From Target ALS

    05 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/09/05/2941064/0/en/NRG-Therapeutics-Awarded-Grant-Funding-from-Target-ALS-to-Support-the-Development-of-mPTP-Inhibitors-as-Novel-Treatments-for-ALS-MND.html

    GLOBENEWSWIRE
    05 Sep 2024
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search